Drug intelligence / Profile preview

bisoprolol + ramipril

Development stage: Unknown
Lead developer: Neopharmed Gentili
Modality: Small Molecules
Administration: Oral

Overview

Bisoprolol + ramipril is a fixed-dose combination (FDC) therapy that combines a beta-blocker (bisoprolol) with an angiotensin-converting enzyme (ACE) inhibitor (ramipril). This combination targets different blood pressure control systems with complementary mechanisms of action. The FDC format is designed to reduce tablet burden, improve treatment adherence, and enhance blood pressure control in patients with hypertension. Clinical studies have demonstrated bioequivalence for the 10/5 mg strength and the absence of clinically relevant pharmacokinetic drug-drug interactions between bisoprolol and ramipril[1][5].

Brand names: RamiBiso APONTIS
Other names: ramipril/bisoprololbisoprolol/ramipril

Targets

ADRB1 (β1)ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on bisoprolol + ramipril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bisoprolol + ramipril.

Explore the full profile